| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04334915 Details | 2022-12-21 Interventional | 2 | 0 | Cenicriviroc Arteritis Inflammation HIV Infections | Industry supporter no longer supporting the study. Protocol A5415's study will run instead. - | |||
| NCT04306692 2018-004604-20 Details | 2022-12-21 Interventional | 4 | 12 | Clomiphene Enclomiphene Inositol Zuclomiphene Polycystic Ovar… Clomiphene Inositol Ovulation Induc… | clomiphene citrate is no longer being considered as standard treatment for polycystic ovary
syndrome - | |||
| NCT03739840 2018-002303-33 Details | 2022-12-21 Interventional | 3 | [1 Refs] | 232 | Padsevonil Drug Resistant … Epilepsy Seizures Drug-Resistant … Focal-Onset Sei… | Based on available data, UCB has decided to stop development of padsevonil as adjunctive
treatment of focal-onset seizure - | ||
| NCT03236805 Details | 2022-12-21 Interventional | 3 | 285 | Ketamine Morphine Pain Management | 285 patients have recruited instead on 496 but we don't want to continue to prolonge the study.
Analysis will be performed on the data we have. - | |||
| NCT02607813 2015-003421-33 Details | 2022-12-21 Interventional | 1 | 142 | Naporafenib Spartalizumab Melanoma NSCLC Other Solid Tum… Ovarian Cancer | - - | |||
| NCT04851834 Details | 2022-12-20 Interventional | 1/2 | 12 | Carboplatin Cisplatin Temozolomide Glioma Advanced Solid … High-grade Glio… Platinum-Resist… Platinum-Resist… | Study was terminated by IP Holder (collaborator), PinotBio Inc. - | |||
| NCT04042116 Details | 2022-12-20 Interventional | 1/2 | - | Nivolumab Neoplasms Advanced Solid … Gynecologic Can… | Company decision - | |||
| NCT03638128 2018-000550-21 Details | 2022-12-20 Interventional | 3 | 75 | Denosumab Osteogenesis Im… Osteogenesis Im… | The study was stopped earlier than planned due to safety concerns about high levels of calcium
in the blood of the participants - | |||
| NCT03982537 Details | 2022-12-19 Interventional | 2 | 0 | Acetylcysteine N-monoacetylcys… Head and Neck N… Head and Neck C… | Concept is withdrawn and a different concept will be submitted the near future. - | |||
| NCT03481556 Details | 2022-12-19 Interventional | 1/2 | 56 | Bortezomib Daratumumab Dexamethasone Dexamethasone a… Melphalan Multiple Myelom… Neoplasms, Plas… | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. On 04 November 2021, the study was terminated early during Phase 2a. | |||
| NCT03272217 NCT03133390 Details | 2022-12-19 Interventional | 2 | 16 | Atezolizumab Bevacizumab Carcinoma, Tran… Urothelial Carc… | Funder decision - | |||
| NCT02987998 Details | 2022-12-19 Interventional | 1 | 9 | Etoposide Pembrolizumab Carcinoma, Non-… Lung Neoplasms Stage IIIA Non-… | higher than expected rate of toxicity & unrealistic timeline to complete trial under company's
proposed plan to reopen - | |||
| NCT02052193 Details | 2022-12-19 Interventional | 2 | 8 | Dabrafenib Vemurafenib Melanoma Metastatic Mela… | Second cohort not opened because Simon-Two_Step model failed - | |||
| NCT04021017 Details | 2022-12-16 Interventional | 1 | 0 | Estradiol Estradiol 17 be… Estradiol 3-ben… Polyestradiol p… Anorexia Anorexia Nervos… | PI Workload - | |||
| NCT03971110 Details | 2022-12-16 Interventional | 4 | [1 Refs] | 9 | Bicalutamide Goserelin Prostatic Neopl… Advanced Prosta… | Due to the limited potential patients pool, the enrollment goal could not be achieved. After
review and communication, the decision to teminate study was made. - | ||
| NCT05496894 Details | 2022-12-15 Interventional | 2 | 0 | Mitoxantrone Multiple Sclero… Sclerosis Relapsing Multi… | Due to the company's project adjustment, decided to stop this study - | |||
| NCT05494619 2021-002968-49 Details | 2022-12-15 Interventional | 3 | 0 | Antibodies Immunoglobulins Immunoglobulins… Rho(D) Immune G… gamma-Globulins Guillain-Barre … Syndrome Guillain-Barré… | This study has been withdrawn due to an internal decision. The decision was not due to any
safety concerns with study drug. - | |||
| NCT04420624 Details | 2022-12-15 Interventional | 2/3 | 54 | Colchicine Infarction Myocardial Infa… Myocardial Infa… | Inclusion period completed - | |||
| NCT03998293 Details | 2022-12-15 Interventional | 4 | 0 | Somatostatin Healthy | Newly available data suggests that measuring proinsulin clearance would not enhance predictive
value of serum proinsulin - | |||
| NCT01584934 2011-006336-23 Details | 2022-12-15 Interventional | 4 | 0 | Sodium Oxybate Fatigue Fatigue Syndrom… Syndrome Chronic Fatigue… | incompatibilities over intellectual property - |